However, resistance to trastuzumab can develop over time in a significant number of patients, reducing its effectiveness and necessitating the development of novel treatment strategies to improve survival rates among HER2+ breast cancer patients [6]. This evidence concerns the gene ERBB2 and breast carcinoma.